Literature DB >> 30149886

Causes of Mortality in the Marfan Syndrome(from a Nationwide Register Study).

Kristian A Groth1, Kirstine Stochholm2, Hanne Hove3, Niels H Andersen4, Claus H Gravholt5.   

Abstract

The Marfan syndrome (MFS) is strongly associated with aortic disease causing a high prevalence of prophylactic aortic surgery, aortic dissection, and sudden death. The aim of the present study was to evaluate mortality in a nationwide Danish MFS population diagnosed by the Ghent II criteria. In a register-based setting, we identified all Danish patients with MFS (n = 412, men n = 215) by assessment of their medical records. We established a gender and age matched control cohort based on 41,000 control patients (men n = 21,500). MFS cases risk time was 6,669 patient years. We applied Cox regression using each case and his/her control as one stratum, adjusting for age and calendar time. We found a significantly decreased lifespan of 50years compared with 60years among controls. The mortality hazard ratio among MFS compared with controls was significantly increased to3.6 (CI 2.8-4.7, p < 0.001); men 4.0 (CI 2.8-5.7, p < 0.001); women 3.2 (CI 2.1-4.8,p < 0.001). Aorta disease represented the main reason for the overall increased mortality with a hazard ratio of 194.6 (CI 67.4-561.7, p < 0.0001); men 208.7 (CI 53.8-809.1, p < 0.001); women 173.4 (CI 31.5-954.5, p < 0.001). In addition, an unexplained mortality due to respiratory illness was not attributed to pneumothorax. Excluding cardiovascular and respiratory causes of death, we found no indication that MFS is associated with increased mortality for other reasons.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2018        PMID: 30149886     DOI: 10.1016/j.amjcard.2018.06.034

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  15 in total

1.  Non-aortic cardiovascular disease in Marfan syndrome: a nationwide epidemiological study.

Authors:  Niels H Andersen; Kristian A Groth; Agnethe Berglund; Hanne Hove; Claus H Gravholt; Kirstine Stochholm
Journal:  Clin Res Cardiol       Date:  2021-04-22       Impact factor: 5.460

2.  Age and sex dependency of thoracic aortopathy in a mouse model of Marfan syndrome.

Authors:  Nazli Gharraee; Yujian Sun; Joseph A Swisher; Susan M Lessner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-10-29       Impact factor: 4.733

Review 3.  Pathophysiology and Pathogenesis of Marfan Syndrome.

Authors:  Sanford M Zeigler; Brandon Sloan; Jeffrey A Jones
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Cardiothoracic surgery and peripheral endovascular intervention in cardiovascular damage from a cohort of orphan rheumatological diseases-epidemiological and survival analysis.

Authors:  Maria Elena Soto; Huitzilihuitl Saucedo-Orozco; Eric Ochoa-Hein; Guering Eid-Lidt; Javier E Anaya-Ayala; Israel Pérez-Torres; Solange Gabriela Koretzky; Pedro A Reyes; Edison Ricardo Espinoza-Saquicela; Ivan Hernandez; Humberto Martinez-Hernandez
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

5.  Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials.

Authors:  Alex Pitcher; Enti Spata; Jonathan Emberson; Kelly Davies; Heather Halls; Lisa Holland; Kate Wilson; Christina Reith; Anne H Child; Tim Clayton; Matthew Dodd; Marcus Flather; Xu Yu Jin; George Sandor; Maarten Groenink; Barbara Mulder; Julie De Backer; Arturo Evangelista; Alberto Forteza; Gisela Teixido-Turà; Catherine Boileau; Guillaume Jondeau; Olivier Milleron; Ronald V Lacro; Lynn A Sleeper; Hsin-Hui Chiu; Mei-Hwan Wu; Stefan Neubauer; Hugh Watkins; Hal Dietz; Colin Baigent
Journal:  Lancet       Date:  2022-08-29       Impact factor: 202.731

6.  NGS analysis in Marfan syndrome spectrum: Combination of rare and common genetic variants to improve genotype-phenotype correlation analysis.

Authors:  Davide Gentilini; Antonino Oliveri; Teresa Fazia; Alessandro Pini; Susan Marelli; Luisa Bernardinelli; Anna Maria Di Blasio
Journal:  PLoS One       Date:  2019-09-19       Impact factor: 3.240

7.  Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial.

Authors:  Michael Mullen; Xu Yu Jin; Anne Child; A Graham Stuart; Matthew Dodd; José Antonio Aragon-Martin; David Gaze; Anatoli Kiotsekoglou; Li Yuan; Jiangting Hu; Claire Foley; Laura Van Dyck; Rosemary Knight; Tim Clayton; Lorna Swan; John D R Thomson; Guliz Erdem; David Crossman; Marcus Flather
Journal:  Lancet       Date:  2019-12-10       Impact factor: 79.321

Review 8.  Cardiomyopathy in Genetic Aortic Diseases.

Authors:  Laura Muiño-Mosquera; Julie De Backer
Journal:  Front Pediatr       Date:  2021-07-15       Impact factor: 3.418

9.  Classification and Interpretation for 11 FBN1 Variants Responsible for Marfan Syndrome and Pre-implantation Genetic Testing (PGT) for Two Families Successfully Blocked Transmission of the Pathogenic Mutations.

Authors:  Songchang Chen; Hongjun Fei; Junyun Zhang; Yiyao Chen; Hefeng Huang; Daru Lu; Chenming Xu
Journal:  Front Mol Biosci       Date:  2021-12-10

Review 10.  The Molecular Genetics of Marfan Syndrome.

Authors:  Qiu Du; Dingding Zhang; Yue Zhuang; Qiongrong Xia; Taishen Wen; Haiping Jia
Journal:  Int J Med Sci       Date:  2021-05-27       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.